TKI-Resistant AML Treatment via Biomarker-Guided Combination Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for acute myeloid leukemia (AML) with FLT3 mutations, including tyrosine kinase inhibitors (TKIs), face challenges such as short duration of response, high rate of relapse, and resistance to salvage chemotherapy, leading to poor overall survival.

Innovation Solution

The methods involve evaluating resistance to TKI therapy in AML by detecting specific biomarkers like CD33, CD44, and phosphorylated BCL2-associated agonist of cell death (pBAD) on AML tumor cells, and administering a combination therapy of a TKI with an inhibitor targeting TKI-activated compensation pathways, such as the JAK-STAT pathway or the NFκB2-MIF-CXCR2 pathway.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If TKI monotherapy is used to treat FLT3-mutated AML, then initial response is achieved, but relapse rate increases and duration of response decreases

Engineering Contradiction:

Improveresponse durationVSAvoidrelapse rate

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent combines TKI therapy with inhibitors of compensatory pathways (JAK-STAT, NFκB2-MIF-CXCR2) to create a multi-target treatment regimen. This combination approach blocks both the primary FLT3-driven signaling and the alternative compensatory pathways that leukemic cells activate to survive TKI treatment, thereby preventing relapse and extending response duration without requiring higher TKI doses.

Inventive Principle:

Principle #5Merging (Combining)

2Reliability

If TKI dosage is increased to overcome resistance, then therapeutic efficacy may improve, but toxicity increases

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidtoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces pathway-specific inhibitors (JAK-STAT inhibitors, NFκB2-MIF-CXCR2 pathway inhibitors) as intermediary agents that selectively block compensatory signaling routes. These intermediaries enable the use of standard TKI doses by providing an alternative mechanism to overcome resistance, avoiding the need to increase TKI dosage and the associated toxicity.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If combination therapy with multiple inhibitors is used, then therapeutic efficacy improves, but treatment complexity increases

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the anti-leukemic strategy into distinct functional modules: (1) TKI to block FLT3-driven signaling, (2) JAK-STAT pathway inhibitor to block one compensatory route, and (3) NFκB2-MIF-CXCR2 pathway inhibitor to block another compensatory route. This modular segmentation allows for systematic combination therapy that addresses multiple resistance mechanisms while maintaining clear therapeutic rationale and potential adaptability.

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS20250123282A1Methods for evaluation and treatment of tyrosine kinase inhibitor (TKI)-resistant acute myeloid leukemia

Publication Date: 2025.04.17 LOMA LINDA UNIVERSITY

AI summary

Disclosed here are methods of evaluating resistance to a tyrosine kinase inhibitor (TKI) therapy of acute myeloid leukemia (AML) in a subject that include detecting the status of CD33, CD44, and phosphorylated BCL2 associated agonist of cell death (pBAD) expression. Also disclosed herein are methods of treating AML in a subject by administering a TKI and one or more inhibitors targeting a TKI-activated compensation pathway to the subject.